Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms
This paper describes a multicentric field study which has evaluated the safety and efficacy of a novel spot on formulation containing emodepside 2.04% w/v, praziquantel 8.14% w/v and tigolaner 9.79% w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 ml/kg body weig...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Current Research in Parasitology and Vector-Borne Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667114X22000243 |
| _version_ | 1811292132905844736 |
|---|---|
| author | Dejan Cvejić Norbert Mencke Gabriele Petry Hannah Ringeisen Hannah Hamburg Klaus Hellmann Donato Traversa Simone Morelli Angela Di Cesare Anastasia Diakou Róbert Farkas |
| author_facet | Dejan Cvejić Norbert Mencke Gabriele Petry Hannah Ringeisen Hannah Hamburg Klaus Hellmann Donato Traversa Simone Morelli Angela Di Cesare Anastasia Diakou Róbert Farkas |
| author_sort | Dejan Cvejić |
| collection | DOAJ |
| description | This paper describes a multicentric field study which has evaluated the safety and efficacy of a novel spot on formulation containing emodepside 2.04% w/v, praziquantel 8.14% w/v and tigolaner 9.79% w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 ml/kg body weight to privately owned cats infected with major intestinal nematodes (Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Uncinaria stenocephala) and/or cestodes (Dipylidium caninum, Taenia taeniaeformis) and/or lungworms (Aelurostrongylus abstrusus, Troglostrongylus brevior). A total of 219 cats from 26 veterinary clinics located in Albania, Greece, Hungary, Italy and Portugal were included in the study. Feces from the cats were examined on a single occasion between Study Day −7 and Day 0 (baseline) and post-treatment (i) twice between Day 7 and Day 14 (± 2) (for intestinal helminths) or (ii) twice between Day 21 (± 2) and Day 28 (± 2) (for lungworms). Cats were allocated into two groups at a ratio of 2:1 (Felpreva®: Profender®, i.e. a commercial control product containing emodepside and praziquantel). Cats infected with intestinal helminths were treated once on Day 0 (i) with Felpreva® (Group 1) or (ii) with Profender® (Group 2). Animals infected with lungworms received a second treatment with Profender® on Day 14 (± 2) regardless of group allocation. Faecal egg or larval count reduction for Felpreva® was 97.47% for intestinal nematodes and 96.80% for lungworms. No cats infected with cestodes at baseline resulted positive after treatment with Felpreva®. However, the low number of cats (n = 10) did not allow for a statistical analysis to be performed. Non-inferiority of Felpreva® compared to Profender® was statistically demonstrated for all target intestinal and respiratory parasites. No adverse events nor application site reactions were observed. These results show that the new topical combination product Felpreva® is highly safe and efficacious in treating infections caused by major species of feline intestinal nematodes, cestodes and lungworms under field conditions. |
| first_indexed | 2024-04-13T04:40:40Z |
| format | Article |
| id | doaj.art-a7e695ff7f6841d69cbdf2a6956760c7 |
| institution | Directory Open Access Journal |
| issn | 2667-114X |
| language | English |
| last_indexed | 2024-04-13T04:40:40Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Current Research in Parasitology and Vector-Borne Diseases |
| spelling | doaj.art-a7e695ff7f6841d69cbdf2a6956760c72022-12-22T03:02:00ZengElsevierCurrent Research in Parasitology and Vector-Borne Diseases2667-114X2022-01-012100098Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungwormsDejan Cvejić0Norbert Mencke1Gabriele Petry2Hannah Ringeisen3Hannah Hamburg4Klaus Hellmann5Donato Traversa6Simone Morelli7Angela Di Cesare8Anastasia Diakou9Róbert Farkas10Klifovet GmbH, Geyerspergerstr. 27, 80689 München, GermanyVetoquinol S.A., 37 rue de la Victoire, 75009 Paris, France; Corresponding author.Bayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, GermanyBayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, GermanyBayer Animal Health GmbH an Elanco Animal Health Company, Alfred Nobel Str. 50, 40789 Monheim, GermanyKlifovet GmbH, Geyerspergerstr. 27, 80689 München, GermanyFaculty of Veterinary Medicine, University of Teramo, Località Piano D’Accio, 64100 Teramo (TE), ItalyFaculty of Veterinary Medicine, University of Teramo, Località Piano D’Accio, 64100 Teramo (TE), ItalyFaculty of Veterinary Medicine, University of Teramo, Località Piano D’Accio, 64100 Teramo (TE), ItalyFaculty of Health Sciences, School of Veterinary Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, GreeceDepartment of Parasitology and Zoology, Faculty of Veterinary Medicine, Szent István University, István u. 2, Budapest 1078, HungaryThis paper describes a multicentric field study which has evaluated the safety and efficacy of a novel spot on formulation containing emodepside 2.04% w/v, praziquantel 8.14% w/v and tigolaner 9.79% w/v (Felpreva®, Vetoquinol) when administered at the intended commercial dose of 0.15 ml/kg body weight to privately owned cats infected with major intestinal nematodes (Toxocara cati, Toxascaris leonina, Ancylostoma tubaeforme, Uncinaria stenocephala) and/or cestodes (Dipylidium caninum, Taenia taeniaeformis) and/or lungworms (Aelurostrongylus abstrusus, Troglostrongylus brevior). A total of 219 cats from 26 veterinary clinics located in Albania, Greece, Hungary, Italy and Portugal were included in the study. Feces from the cats were examined on a single occasion between Study Day −7 and Day 0 (baseline) and post-treatment (i) twice between Day 7 and Day 14 (± 2) (for intestinal helminths) or (ii) twice between Day 21 (± 2) and Day 28 (± 2) (for lungworms). Cats were allocated into two groups at a ratio of 2:1 (Felpreva®: Profender®, i.e. a commercial control product containing emodepside and praziquantel). Cats infected with intestinal helminths were treated once on Day 0 (i) with Felpreva® (Group 1) or (ii) with Profender® (Group 2). Animals infected with lungworms received a second treatment with Profender® on Day 14 (± 2) regardless of group allocation. Faecal egg or larval count reduction for Felpreva® was 97.47% for intestinal nematodes and 96.80% for lungworms. No cats infected with cestodes at baseline resulted positive after treatment with Felpreva®. However, the low number of cats (n = 10) did not allow for a statistical analysis to be performed. Non-inferiority of Felpreva® compared to Profender® was statistically demonstrated for all target intestinal and respiratory parasites. No adverse events nor application site reactions were observed. These results show that the new topical combination product Felpreva® is highly safe and efficacious in treating infections caused by major species of feline intestinal nematodes, cestodes and lungworms under field conditions.http://www.sciencedirect.com/science/article/pii/S2667114X22000243CatFelpreva®Intestinal helminthsLungwormsTreatment |
| spellingShingle | Dejan Cvejić Norbert Mencke Gabriele Petry Hannah Ringeisen Hannah Hamburg Klaus Hellmann Donato Traversa Simone Morelli Angela Di Cesare Anastasia Diakou Róbert Farkas Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms Current Research in Parasitology and Vector-Borne Diseases Cat Felpreva® Intestinal helminths Lungworms Treatment |
| title | Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms |
| title_full | Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms |
| title_fullStr | Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms |
| title_full_unstemmed | Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms |
| title_short | Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms |
| title_sort | multicenter randomized and blinded european field study evaluating the efficacy and safety of felpreva r a novel spot on formulation containing tigolaner emodepside and praziquantel in treating cats with mixed infection with intestinal nematodes cestodes and or lungworms |
| topic | Cat Felpreva® Intestinal helminths Lungworms Treatment |
| url | http://www.sciencedirect.com/science/article/pii/S2667114X22000243 |
| work_keys_str_mv | AT dejancvejic multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT norbertmencke multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT gabrielepetry multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT hannahringeisen multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT hannahhamburg multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT klaushellmann multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT donatotraversa multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT simonemorelli multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT angeladicesare multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT anastasiadiakou multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms AT robertfarkas multicenterrandomizedandblindedeuropeanfieldstudyevaluatingtheefficacyandsafetyoffelprevaanovelspotonformulationcontainingtigolaneremodepsideandpraziquantelintreatingcatswithmixedinfectionwithintestinalnematodescestodesandorlungworms |